Stage 1 cancer detection

Microarrays carrying all possible RNA-synthesis frameshift error neo-peptides can be produced at scale.

A small amount of patient blood is applied to the microarrays which results in an antibody-based diagnostic for the early detection of cancer and companion products.

The neo-peptide diagnostic tests will be simple to conduct, and yield highly sensitive results, even at stage 1 cancer.

Immunotherapy Response Predictor

Preliminary Positive results on renal cancer, lung cancer and mixed rare cancers for check point inhibitor treatments. Technology enables prediction of responders and non-responders to treatment as well as prediction of adverse events. Read more here.

Therapeutic vaccines

The frameshift peptide arrays are used to identify those neo-peptides that recurrently bind antibodies in cancer patient blood.

Antibody binding activity to some neo-peptides is shared among patients with the same type of cancer; other binding activity is consistently shared among patients with different cancer types.

These shared, antibody-eliciting neo-peptides serve as neoantigens to include in an inventory of off-the-shelf FAST (Frameshift Antigen Shared Therapeutic) Vaccines.

Prophylactic vaccines

Clinical Studies are in progress to determine the potential impact of prophylactic vaccines intended to prevent the occurrence of most major cancers. This includes the ongoing VACCS trials.

The same frameshift peptide arrays are used to identify collections of neo-peptides that collectively provide for blood-antibody binding activity profiles that span most major cancers.